Progressive Pulmonary Fibrosis: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report

Published: April 01, 2026 Report Code: GDHCHT709-ST

Select Item

Explore the future of the progressive pulmonary fibrosis (PPF) therapeutics market with GlobalData’s market opportunity analysis report. Analyze PPF market forecasts, pipeline drugs, disease-modifying therapies, competitive landscape, unmet needs, epidemiology, and treatment trends across the US, Europe, and Japan through 2035. Gain insight into progressive pulmonary fibrosis drug development, market growth drivers, late-stage pipeline products, and strategic opportunities shaping the respiratory therapeutics industry.

Why Does the Progressive Pulmonary Fibrosis Market Matter for Your Business?

The progressive pulmonary fibrosis (PPF) therapeutics market is entering a new phase of development, driven by growing diagnosis rates, expanding research activity, and the advancement of late-stage disease-modifying therapies.

This report provides a comprehensive analysis of the PPF market across the seven major markets (7MM) — the US, France, Germany, Italy, Spain, the UK, and Japan — including treatment trends, pipeline products, competitive dynamics, unmet needs, and market forecasts through 2035.

You can use this report to:

  • Understand the current and future outlook of the PPF therapeutics market
  • Analyze pipeline products and emerging disease-modifying therapies
  • Benchmark leading companies and competitive positioning
  • Evaluate unmet clinical and commercial opportunities
  • Assess epidemiology, diagnosis trends, and treatment adoption
  • Identify licensing, partnership, and investment opportunities
  • Support market access, commercialization, and strategic planning decisions

Built on GlobalData’s proprietary pharmaceutical intelligence and analyst expertise, this report helps support business development, pipeline evaluation, and competitive strategy across the respiratory therapeutics sector.

Key Insights in the Progressive Pulmonary Fibrosis Therapeutics Market

The report highlights how innovation, diagnosis expansion, and late-stage pipeline activity are reshaping the future of the PPF therapeutics market.

Key themes covered include:

  • The PPF therapeutics market totaled $1.3 billion across the seven major markets in 2025
  • The market is projected to grow at a CAGR of 8.4% to reach $2.9 billion by 2035
  • Growth is primarily driven by the launch of new disease-modifying therapies (DMTs)
  • Combination treatment regimens are expected to diversify the therapeutic landscape
  • Increasing diagnosis rates are supporting market expansion
  • The US accounted for approximately 80% of 7MM sales in 2025
  • The US share is projected to increase to approximately 84% by 2035
  • Higher pricing, delayed generic erosion, and faster uptake of novel therapies continue to support US market dominance

In addition, the report examines future R&D trends, pipeline innovation, and evolving competitive dynamics within the global PPF market.

Scope

What Will You Learn from This Progressive Pulmonary Fibrosis Market Report?

This report provides insight into:

  • Progressive pulmonary fibrosis epidemiology and disease management

  • Current treatment landscape and future therapy outlook

  • PPF market size and forecasts through 2035

  • Disease-modifying therapies and late-stage pipeline analysis

  • Annual therapy cost and anticipated drug sales

  • Competitive assessment of marketed and pipeline therapies

  • Unmet needs and emerging treatment opportunities

  • KOL insights and future market trends

  • Industry drivers and barriers influencing market growth

The report also includes detailed analysis across:

  • United States

  • France

  • Germany

  • Italy

  • Spain

  • United Kingdom

  • Japan

Target Buyers for This Report

This report may be valuable for:

  • Pharmaceutical companies

  • Respiratory therapeutics developers

  • Biotechnology firms

  • Drug commercialization teams

  • Licensing and business development professionals

  • Healthcare investors and private equity firms

  • Market access and reimbursement specialists

  • Competitive intelligence teams

  • Clinical strategy and R&D executives

  • Healthcare consulting firms

  • Institutional and pharmaceutical analysts

In addition, companies evaluating expansion opportunities within rare respiratory diseases and fibrosis therapeutics may use this report to support strategic planning and pipeline prioritization.

How Companies Use This PPF Therapeutics Market Analysis Report

Pharmaceutical companies, investors, and healthcare strategists can use this report to benchmark pipeline activity, assess commercial opportunities, and refine long-term growth strategies.

For example:

  • Pharmaceutical companies may use the report to evaluate competitive positioning and pipeline differentiation opportunities

  • Biotechnology firms can identify licensing and co-development opportunities linked to emerging therapies

  • Investors may assess market growth potential and late-stage pipeline commercial viability

  • Commercial strategy teams can benchmark therapy adoption and pricing trends across major markets

  • Consulting firms may use the insights to support respiratory market expansion and commercialization projects

  • Market access teams can evaluate reimbursement and treatment landscape developments influencing adoption

Reasons to Buy

Benchmark PPF Therapeutics Trends Against Leading Industry Players

This report helps you benchmark the progressive pulmonary fibrosis therapeutics market against leading pharmaceutical companies and emerging pipeline innovators.

It provides comparative insight into:

  • Pipeline product development

  • Market growth forecasts

  • Disease-modifying therapy trends

  • Competitive market positioning

  • R&D and innovation activity

  • Treatment adoption dynamics

  • Commercial opportunities across the 7MM

As a result, you can better understand how leading companies are positioning themselves within the evolving pulmonary fibrosis therapeutics landscape.

Built on Trusted GlobalData Pharmaceutical Intelligence

GlobalData’s Progressive Pulmonary Fibrosis Market Opportunity Analysis report is built on proprietary pharmaceutical databases, therapy pipeline intelligence, and deep respiratory disease expertise.

Trusted by Fortune 500 pharmaceutical companies, biotechnology firms, investors, and healthcare organizations, GlobalData’s intelligence helps organizations monitor market developments and identify emerging commercial opportunities.

In addition, GlobalData’s analysts bring decades of expertise across respiratory therapeutics, rare disease markets, pharmaceutical forecasting, and competitive intelligence.

Act Now to Identify Opportunities in the Progressive Pulmonary Fibrosis Therapeutics Market

The progressive pulmonary fibrosis therapeutics market continues to evolve through pipeline innovation, expanding diagnosis rates, and the emergence of new disease-modifying therapies.

This report can help you monitor market trends, benchmark competitive activity, and identify strategic growth opportunities across the global PPF therapeutics market through 2035.

Boehringer Ingleheim
Bristol-Myers Squibb
Avalyn Pharma
United Therapeutics
Insmed Inc
Roche
InterMune
Brainomix

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of PPF

3.2. Pathophysiology of PPF

3.3. PPF Market SWOT Analysis

4. Epidemiology

4.1. Diagnosed Prevalent Cases of PPF, Both Sexes, N, Ages ≥18 Years, 2025–35

4.2. Sex-Specific Diagnosed Prevalent Cases of PPF, N, Ages ≥18 Years, 2025

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Ofev (nintedanib)

5.4. Product Profile: Jascayd (nerandomilast)

5.5. Product Profile: Esbriet (pirfenidone)

5.6. Patient Flow

6. Unmet Needs and Opportunities

6.1. Unmet Needs in PPF

6.2. Therapeutic efficacy beyond slowing of FVC decline

6.3. Delays in diagnosis and treatment initiation

6.4. Limited treatment options for patients and high toxicity

6.5. Lack of predictive biomarkers to identify patients at risk of progression

7. R&D Strategies

7.1. Trends in Clinical Trial Design in PPF

7.2. Trends in Deal-Making in ILDs

8. Pipeline Assessment

8.1. Pipeline Overview

8.2. Late-Stage Pipeline Agents for PPF

8.3. Product Profile: admilparant

8.4. Product Profile: Tyvaso (treprostinil)

8.5. Product Profile: treprostinil palmitil

8.6. Product Profile: AP-01

8.7. PPF: Clinical Trials (Phase I/II/III) Overview

9. Market Outlook

9.1. PPF Market Forecast by Country, 2025-35

9.2. PPF Market Forecast by Drug Class, 2025–35

9.3. PPF Market Drivers and Barriers

10. Appendix

10.1. Primary Research: KOL information

10.2. Bibliography

10.3. About the Authors

11. Contact Us

Progressive Pulmonary Fibrosis: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2035 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Progressive Pulmonary Fibrosis: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2035 in real time.

  • Access a live Progressive Pulmonary Fibrosis: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more